Finance & Acquisition: Seattle Genetics

Parents

2010: Has generated more than $145 million from ADC licensing, and has the potential to receive significant future milestones and royalties for ADCs developed by collaborators (2010)
2011: SeaGen Ends March With $456M Cash (2011)
2011: SeaGen Tacks on $23M (2011)
2011: Seattle Genetics to receive $8 million upfront payment, over $200 million in potential milestone payments plus royalties under Pfizer single-target collaboration
2018: Pieris, Seattle Genetics pen $1.2B biobucks pact for next-gen cancer drugs
2018: Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline_businesswire
2018: Seattle Genetics: A Buy After Brilliant Acquisition - Seattle Genetics, Inc. (NASDAQ:SGEN)
2019: Seattle Genetics' Acquisition Of Cascadian Therapeutics Pays Off_seekingalpha.com
2020: Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals
2022: Seagen Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: How Pfizer’s $43 billion acquisition of Seagen could impact the biotech industry in Seattle_ geekwire
Cascadian Therapeutics (CASC)
Revenue (2018): $654.7 million
Revenue (2019): $916 millio